89324-16-3

Usage

Uses

Used in Pharmaceutical Industry:
Nicotinonitrile, 4-hydroxy(7CI) is used as a key intermediate in the synthesis of various pharmaceutical products. Its unique chemical structure allows for the development of new drugs with potential therapeutic applications. Nicotinonitrile, 4-hydroxy(7CI)'s reactivity and functional groups enable the formation of diverse chemical entities, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical industry, Nicotinonitrile, 4-hydroxy(7CI) serves as an essential intermediate for the production of various agrochemicals. Its incorporation into the synthesis process allows for the development of new pesticides, herbicides, and other agricultural chemicals that can improve crop yield and protect plants from pests and diseases.
Used in Organic Synthesis for Industrial Applications:
Nicotinonitrile, 4-hydroxy(7CI) is also utilized in the synthesis of various organic compounds for industrial applications. Its versatile chemical properties make it a valuable building block for the creation of new materials, dyes, and other specialty chemicals. Nicotinonitrile, 4-hydroxy(7CI)'s reactivity and functional groups facilitate the formation of a wide range of chemical entities, contributing to the innovation and development of various industries.

InChI:InChI=1/C6H4N2O/c7-3-5-4-8-2-1-6(5)9/h1-2,4H,(H,8,9)

Upstream product

• 959972-32-8 5-(dimethylamino)-2-[(dimethylamino)methylene]-3-oxopent-4-enenitrile 
• 631-61-8 ammonium acetate 
• 626-64-2 pyridin-4-ol 
• 557-21-1 zinc(II) cyanide 
• 89282-03-1 3-iodo-pyridin-4-ol 

Downstream Products

• 1174709-11-5 4-hydroxy-5-iodopyridine-3-carbonitrile 

Relevant academic research and scientific papers

INHIBITORS OF BRUTON'S TYROSINE KINASE

The present invention relates to a new compound of formula I: or pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein: V1 is C or N, V2 is C(R2) or N, whereby if V1 is C then V2 is N, if V1 is C then V2 is C(R2), or if V1 is N then V2 is C(R2); each n, k is independently 0, 1; each R2, R11 is independently H, D, Hal, CN, NR'R", C(O)NR'R", C1-C6 alkoxy; R3 is H, D, hydroxy, C(O)C1-C6 alkyl, C(O)C2-C6 alkenyl, C(O)C2-C6 alkynyl, C1-C6 alkyl; R4 is H, Hal, CN, CONR'R", hydroxy, C1-C6 alkyl, C1-C6 alkoxy; L is CH2, NH, O or chemical bond; R1 is selected from the group of the fragments, comprising: Fragment 1, Fragment 2, Fragment 3 each A1, A2, A3, A4 is independently CH, N, CHal; each A5, A6, A7, A8, A9 is independently C, CH or N; R5 is H, CN, Hal, CONR'R", C1-C6 alkyl, non-substituted or substituted by one or more halogens; each R' and R" is independently selected from the group, comprising H, C1-C6 alkyl, C1-C6 cycloalkyl, aryl; R6 is selected from the group: [formula II] each R7, R8, R9, R10 is independently vinyl, methylacetylenyl; Hal is CI, Br, I, F, which have properties of inhibitor of Bruton's tyrosine kinase (Btk), to pharmaceutical compositions containing such compounds, and their use as pharmaceuticals for treatment of diseases and disorder.

5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS

Described herein are compounds of formula I: wherein G is and pharmaceutically acceptable salts thereof, wherein J, X, R1, R2, R11, R12' and p are as defined herein. Also provided herein are methods of making the compounds of formula I, and methods of using these compounds for inhibiting or treating a pathological condition or disorder linked to or mediated by a protein kinase in a mammal.

Substituted Cyanopyridines as protein kinase inhibitors

The present teachings provide compounds of formula I and their pharmaceutically acceptable salts, hydrates, and esters, wherein R1, R2, and X are as defined herein. The present teachings also provide methods of making the compounds of formula I, and methods of treating autoimmune and inflammatory diseases by administering a therapeutically effective amount of a compound or compounds of formula I to a mammal including a human.